Intracellular Therapies Inc Rated 57% by Value Investor Model

Stocks show potential as Intracellular Therapies Inc achieves a 57% score based on Benjamin Graham's Value Investor model, indicating decent fundamentals though some criteria fail.

Date: 11-02-2025

AI Rating: 5

Earnings Per Share (EPS): The report does not provide specific EPS data for INTRA-CELLULAR THERAPIES INC, indicating a lack of information on earnings performance.

Revenue Growth: The analysis indicates a FAIL for the sales criterion, suggesting potential issues with revenue growth that could negatively impact investor sentiment and stock performance.

Net Income: No specific data on net income is mentioned in the text.

Profit Margins: There is no information provided regarding profit margins, limiting the assessment of the company's profitability.

Free Cash Flow (FCF): The report lacks details on free cash flow, which is important for evaluating financial health.

Return on Equity (ROE): The text does not include any information about return on equity, leaving another important metric unexplored.

Despite this, INTRA-CELLULAR THERAPIES INC receives a 57% rating based on various valuation metrics, primarily influenced by its P/E ratio (PASS) and Current Ratio (PASS). However, failures in sales and long-term EPS growth signal caution for investors. The failures can indicate potential challenges in maintaining a strong growth trajectory, possibly pressuring stock prices negatively.

Stocks: ITCI